# Clinical trials recruiting in West Virginia: 345 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 345 trials recruiting or not yet recruiting with a site in West Virginia, as read on November 19, 2026.

## The full list

Clinical trials recruiting in West Virginia: 345 rows for $17.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/west-virginia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 345
- Recruiting or not yet: 345
- Read on: November 19, 2026

## Trials

The 25 newest of 345, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| October 30, 2026 | NCT07907328 | FUS Neuromodulation for Binge Eating Disorder | Sponsor not shown (see the record) | Not applicable | Not yet recruiting | Binge-Eating Disorder | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907328) |
| October 28, 2026 | NCT07900841 | FUS Neuromodulation for PTSD | West Virginia University | Not applicable | Not yet recruiting | Post Traumatic Stress Disorder PTSD | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900841) |
| September 28, 2026 | NCT07843576 | The ICEC Cluster Trial: Integrated Community Engagement Collaborative for Youth Substance Use Prevention in Rural America | West Virginia University | Not applicable | Not yet recruiting | Substance Use (Drugs, Alcohol), Tobacco Use, Adolescent Substance Use | 25,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843576) |
| September 14, 2026 | NCT07817173 | Feasibility of HISA During TURBT for NMIBC | CAMC Health System | Not applicable | Not yet recruiting | Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817173) |
| September 14, 2026 | NCT07817147 | CREO - Microwave Ablation Feasibility Study | Banner Health | Not applicable | Recruiting | Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817147) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 9, 2026 | NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With... | Vividion Therapeutics, Inc. | Phase 2 | Recruiting | Colorectal Adenocarcinoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811193) |
| August 31, 2026 | NCT07794579 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1... | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal | 2,001 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794579) |
| August 28, 2026 | NCT07792226 | ENLIGHT Trial: ESG With Fundal Mucosal Ablation | West Virginia University | Not applicable | Recruiting | Obesity, Obesity (Body Mass Index \>30 kg/m2) | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07792226) |
| August 26, 2026 | NCT07786896 | Evaluation of Dependence and Nicotine Replacement Therapy-Supported Cessation Efforts Among Regular Electronic Cigarette Use | West Virginia University | Phase 4 | Not yet recruiting | E Cigarette Use, Cessation, Tobacco, Cessation, Nicotine | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786896) |
| August 25, 2026 | NCT07784855 | Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer | West Virginia University | Not applicable | Recruiting | Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Oropharynx... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784855) |
| August 20, 2026 | NCT07775495 | Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure | Ecotera Health LLC | Observational | Recruiting | Healthy Adult Participants | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775495) |
| August 12, 2026 | NCT07761117 | A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | AstraZeneca | Phase 3 | Recruiting | Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | 6,950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761117) |
| August 7, 2026 | NCT07753603 | Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) | Sling Therapeutics, Inc. | Phase 3 | Recruiting | Thyroid Eye Disease, TED, Graves Orbitopathy | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753603) |
| August 5, 2026 | NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC)... | Hoffmann-La Roche | Phase 2 | Recruiting | Breast Cancer, Diabetes Type II | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748208) |
| July 15, 2026 | NCT07705555 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Diabetic Retinopathy, Macular Edema | 960 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705555) |
| July 2, 2026 | NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination... | Bristol-Myers Squibb | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680790) |
| June 30, 2026 | NCT07675135 | A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | Harmony Biosciences Management, Inc. | Phase 3 | Recruiting | EDS, Cataplexy, Fatigue, Narcolepsy | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675135) |
| June 29, 2026 | NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | TriGemX Bio, Inc. | Phase 3 | Recruiting | Acute Migraine | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674654) |
| June 25, 2026 | NCT07667803 | A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM | AstraZeneca | Phase 3 | Recruiting | Weight Management | 4,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667803) |
| June 23, 2026 | NCT07662213 | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine... | AstraZeneca | Phase 3 | Recruiting | Type 2 Diabetes Mellitus | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662213) |
| June 23, 2026 | NCT07662109 | A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2... | AstraZeneca | Phase 3 | Recruiting | Type 2 Diabetes Mellitus | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662109) |
| June 23, 2026 | NCT07662083 | Trans Auricular Vagal Nerve Stimulation in Patients With IBS-C | West Virginia University | Not applicable | Not yet recruiting | Irritable Bowel Syndrome (IBS-C) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662083) |
| June 12, 2026 | NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | TriGemX Bio, Inc. | Phase 3 | Recruiting | Migraine | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645924) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| West Virginia University | Morgantown | 67 |
| West Virginia University Healthcare | Morgantown | 51 |
| Camden Clark Medical Center | Parkersburg | 30 |
| Edwards Comprehensive Cancer Center | Huntington | 29 |
| United Hospital Center | Bridgeport | 26 |
| WVUH-Berkely Medical Center | Martinsburg | 22 |
| Vandalia Health/CAMC Institute for Academic Medicine | Charleston | 21 |
| Wheeling Hospital/Schiffler Cancer Center | Wheeling | 16 |
| West Virginia University Charleston Division | Charleston | 12 |
| Princeton Community Hospital | Princeton | 11 |
| West Virginia University Cancer Institute | Morgantown | 9 |
| Charleston Area Medical Center | Charleston | 9 |
| West Virginia University Hospital | Morgantown | 8 |
| West Virginia University Medicine | Morgantown | 4 |
| WVU Cancer Institute | Morgantown | 4 |
| J.W. Ruby Memorial Hospital | Morgantown | 4 |
| Marshall Health | Huntington | 4 |
| Rheumatology & Pulmonary Clinic | Beckley | 3 |
| West Virginia Clinical and Translational Science Institute | Morgantown | 3 |
| WVU Rockefeller Neuroscience Institute | Morgantown | 3 |
| West Virginia University Hospitals | Morgantown | 3 |
| United BioSource LLC | Morgantown | 2 |
| Frontier Clinical Research, LLC | Kingwood | 2 |
| West Virginia University - Morgantown | Morgantown | 2 |
| University Physicians and Surgeons Inc, dba Marshall Health | Huntington | 2 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 6 |
| Phase 1/2 | 6 |
| Phase 2 | 46 |
| Phase 2/3 | 16 |
| Phase 3 | 128 |
| Phase 4 | 14 |
| Not applicable | 73 |
| Observational | 55 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 18 |
| Breast Neoplasms | 15 |
| Lung Neoplasms | 11 |
| Cardiovascular Diseases | 10 |
| Ovarian Neoplasms | 10 |
| Diabetes Mellitus, Type 2 | 9 |
| Heart Failure | 9 |
| Migraine Disorders | 8 |
| Urinary Bladder Neoplasms | 8 |
| Neoplasms | 8 |
| Leukemia, Myeloid, Acute | 7 |
| Prostatic Neoplasms | 7 |
| Melanoma | 7 |
| Coronary Artery Disease | 7 |
| Pulmonary Disease, Chronic Obstructive | 6 |
| Stroke | 6 |
| Pancreatic Neoplasms | 6 |
| Colorectal Neoplasms | 6 |
| Opioid-Related Disorders | 6 |
| Neoplasm Metastasis | 6 |
| Colonic Neoplasms | 5 |
| Hematologic Neoplasms | 5 |
| Hypertension | 4 |
| Obesity | 4 |
| Multiple Myeloma | 4 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| West Virginia University | 28 |
| National Cancer Institute (NCI) | 25 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 22 |
| NRG Oncology | 12 |
| Alliance for Clinical Trials in Oncology | 12 |
| SWOG Cancer Research Network | 10 |
| Children's Oncology Group | 10 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 7 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 7 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 6 |
| ECOG-ACRIN Cancer Research Group | 6 |
| [Boston Scientific Corporation](https://specstream.ai/data/clinical-trials/company/boston-scientific-corporation) | 5 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 4 |
| CAMC Health System | 4 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| Duke University | 3 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 3 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 3 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 3 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 3 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 3 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 2 |
| Sling Therapeutics, Inc. | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| GIE Medical | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in West Virginia

- [High schools in West Virginia, United States](https://specstream.ai/data/businesses/high-schools/west-virginia-united-states)
- [Banks and credit unions in West Virginia, United States](https://specstream.ai/data/businesses/banks-and-credit-unions/west-virginia-united-states)
- [Preschools in West Virginia, United States](https://specstream.ai/data/businesses/preschools/west-virginia-united-states)
- [Hospices in West Virginia, United States](https://specstream.ai/data/businesses/hospices/west-virginia-united-states)
- [Breakfast and brunch restaurants in West Virginia, United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/west-virginia-united-states)
- [Psychology practices in West Virginia, United States](https://specstream.ai/data/businesses/psychology-practices/west-virginia-united-states)
